Name: Acarbose
Brand: Selleck Chemicals
SKU: S1271
Availability: InStock
Rating: 5 (6 reviews)

Jump to

Quality Control

Batch: Purity: 100.00%

100.00

Related Targets	Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Mitochondrial Metabolism Casein Kinase
Other Carbohydrate Metabolism Inhibitors	2-DG (2-Deoxy-D-glucose) Bromopyruvic acid (3-BP) Dorzagliatin 1-Deoxynojirimycin LY2608204 Voglibose AZD1656 FBPase-1 inhibitor-1 4',7-Dimethoxy-5-Hydroxyflavone BI-9787

Solubility

In vitro
Batch:

DMSO : 129 mg/mL (199.81 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 129 mg/mL

Ethanol : 8 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5mg/ml (7.74mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.33mg/ml (0.51mM)	Taking the 1 mL working solution as an example, add 50 μL of 6.6 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	645.6	Formula	C₂₅H₄₃NO₁₈	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	56180-94-0	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	BAY g 5421,Prandase, Precose, Glucobay, Bay-g 5421			SMILES	CC1C(C(C(C(O1)OC2C(OC(C(C2O)O)OC3C(OC(C(C3O)O)O)CO)CO)O)O)NC4C=C(C(C(C4O)O)O)CO

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	alpha-glucosidase
In vitro	This compound reversibly inhibits intestinal alpha-glucosidases, enzymes responsible for the metabolism of complex carbohydrates into absorbable monosaccharide units.
In vivo	Acarbose reduces the absorption of monosaccharides derived from dietary carbohydrates, which play an important role in the metabolism and toxicity of some chemical compounds. This compound alone potentiates carbon tetrachloride (CCl4) and acetaminophen (AP) hepatotoxicity, as evidenced by significantly increased levels of both alanine transaminase (ALT) and aspartate transaminase (AST) in the plasma of rats pretreated with this compound. This treatment suppresses weight gain and the development of hepatic steatosis in sqstm1 gene knockout mice. This compound treatment up-regulates hepatic expression of the pparalpha, ucp-2, and abca1 genes, as well as srebp1c, pparalpha, and ppargamma in adipose tissue. This compound-treated rats have lower body weights at 3 months of age with unaltered food consumption, and a similar effect is seen with a high-fructose diet in the JCR:LA-corpulent rat. This chemical markedly improves postprandial hyperglycemia, postprandial insulin level, total cholesterol, triglyceride, and free fatty acid level in Goto-Kakizaki (GK) rats. This compound efficiently reduces the number of monocytes adherent to aortic endothelial layer, improves acetylcholine-dependent vasodilatation, and reduces intimal thickening of the aorta in GK rats.
References	[1] https://pubmed.ncbi.nlm.nih.gov/8893066/ [2] https://pubmed.ncbi.nlm.nih.gov/9862862/ [3] https://pubmed.ncbi.nlm.nih.gov/19207582/ [4] https://pubmed.ncbi.nlm.nih.gov/8474319/ [5] https://pubmed.ncbi.nlm.nih.gov/16696939/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2025-08-06)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07074379	RECRUITING	Painless Chronic Pancreatitis	Changhai Hospital	2025-07-21
NCT07122102	NOT_YET_RECRUITING	Type 2 Diabetes	Haisco Pharmaceutical Group Co., Ltd.	2025-10-01
NCT07711171	RECRUITING	Type 2 Diabetes Mellitus; Cognitive Impairment	Fudan University	2024-08-19	PHASE4
NCT05487859	WITHDRAWN	Kidney Cancer	University of Alabama at Birmingham	2025-12-31	PHASE2
NCT07436585	COMPLETED	Diabetes; Diabetes Complications; Diabetic Neuropathy	Shifa International Hospital	2025-09-01	PHASE1
NCT05487859	Not yet recruiting	Kidney Cancer	University of Alabama at Birmingham	2025-10-05	Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Acarbose Carbohydrate Metabolism chemical

Chemical Structure

Molecular Weight: 645.6